Photodynamic Therapy With Hydrogel Dressing for Chronic Wounds

Status Recruiting

Clinical Trial Summary

63 patients with chronic infectious wounds were enrolled in the controlled study. They were randomly divided into three groups equally. Group 1 (Grp.1): The patients received hydrogel dressing change at three days intervals. Group 2 (Grp.2): The patients received ALA-PDT treatment at ten days intervals for 4 sessions. Groups 3 (Grp.3): The patients received ALA-PDT at ten days intervals for 4 sessions combined with hydrogel dressing change every three days intervals. The wound healing rate, total effective rate, patient satisfaction, adverse reaction, and recurrence were assessed in all groups.

Clinical Trial Description

Randomly divide the enrolled patients into three groups for treatment by utilizing SAS software (SAS Institute, Cary, NC, U.S.A.). Initially, the wound pus and secretions were washed three times with a sterile saline solution. Subsequently, surgical instruments were employed to debride the wound, particularly the necrotic tissue, as well as any carrion and foreign bodies within the wound bed and cavity, with care being taken to avoid injury to nerves and blood vessels in the surrounding area. Grp.1 was covered with hydrogel dressing (PAUL HARTMANN AG, Germany) and replaced 2-3 times a week with topical mupirocin ointment three times a day. Grp.2 received photodynamic therapy only. Grp.3 accepted PDT, then coated with hydrogel dressing as mentioned above. The treatment protocol of PDT is described as follows: after thorough debridement, ALA (Shanghai Fudan-Zhang jiang Bio-Pharmaceutical Co. Ltd, China) in an oil-in-water emulsion was smeared on the wound. After covering with dark plastic film for 3h, the wounds were illuminated by a light-emitting diode (LED) red light (Shenzhen Lifotronic Technology Co., Ltd, China). After the operation, a cold ice compress can be used to relieve the swelling and pain. Then, the hydrogel was uniformly applied to the wound and its surroundings (Grp.3). Grp.2 and Grp.3 received PDT at an interval of ten days for 4 sessions. In all groups, treatment responses and adverse reactions were recorded. All patients received the treatment as mentioned above and then evaluated the clinical outcome. After the end of the treatment, all patients returned for follow up at weeks 2, 4, 8 and 12. ;

Study Design

Related Conditions & MeSH terms

Photodynamic Therapy

Clinical Trial Details

NCT number	NCT06445699
Study type	Interventional
Source	Army Medical University, China
Contact	Rui Yin, MD, PhD
Phone	13101201667
Email	swyinrui@163.com
Status	Recruiting
Phase	N/A
Start date	January 1, 2023
Completion date	June 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06052033` - Comparison of 5-ALA Photodynamic Therapy and CO2 Laser for Treating Persistent Low-Grade Cervical Lesions With High-Risk HPV Infection	N/A
Recruiting	`NCT05031923` - Treatment of Intrabony Defects With Simvastatin and Antimicrobial Photodynamic Therapy	N/A
Completed	`NCT04037709` - Photodynamic Therapy in Patients With Gingivitis	N/A
Recruiting	`NCT05043935` - The Effect of Leukocyte and Platelet-rich Fibrin With Antimicrobial Photodynamic Therapy in Aggressive Periodontitis	N/A
Not yet recruiting	`NCT06437288` - Hematoporphyrin Photodynamic Therapy for Esophageal Cancer	Phase 2
Completed	`NCT01756313` - Optimizing Uptake of Methylaminolevulinat With Fractional Ablative Laser Technique	Phase 4
Withdrawn	`NCT03960125` - Photodynamic Therapy and Microvesicles	Early Phase 1
Recruiting	`NCT01349361` - Treatment of Basal Cell Carcinomas With Methyl Aminolevulinate and Daylight	Phase 2
Not yet recruiting	`NCT06468540` - Combination of Micropulse Laser With or Without Photodynamic Therapy for Chronic Central Serous Chorioretinopathy
Recruiting	`NCT05688904` - The Effect of Topical Imipramine on Pain and Effectiveness of Topical Photodynamic Therapy	Phase 1
Completed	`NCT04037475` - Treatment of Herpes Labialis by Photodynamic Therapy	N/A
Recruiting	`NCT04689243` - Low Concentration ALA-PDT in Treatment of Skin Ulcer	N/A
Recruiting	`NCT06311890` - Study to Evaluate the Efficacy, Safety and Tolerability of Photodynamic Therapy(PDT) With Chlorin-e6 in Treating Moderate to Severe Acne	Phase 2
Enrolling by invitation	`NCT04223570` - Portable Measurement of Protoporphyrin IX in the Skin
Enrolling by invitation	`NCT05820750` - Clinical and Radiographic Evaluation of Photodynamic Therapy for Root Canal Treatment of Primary Molars	N/A
Completed	`NCT03643744` - Photodynamic Therapy-Induced Immune Modulation: Part III	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.